Garetosmab: Regeneron's Activin A Antibody Nearly Shuts Off Bone Growth in FOP - and Helps Save Muscle in Obesity (July 17, 2026)
Table of Contents
A disease that turns muscle into bone
Fibrodysplasia ossificans progressiva (FOP) is one of the cruelest disorders in medicine: a single genetic mutation causes the body to grow new bone inside its own muscles, tendons and ligaments, a process called heterotopic ossification (HO). Over time this second skeleton locks joints in place. HO of the jaw, spine, hip and rib cage can make it hard to speak, eat, walk and breathe. Most people with FOP are wheelchair-bound by age 30, and median survival is around 56 years. It is ultra-rare - roughly 900 diagnosed cases worldwide - and until now there has been no therapy shown to reduce the number and volume of new bone lesions. Regeneron's garetosmab is aiming to be the first.
What garetosmab is
Garetosmab (REGN2477) is a fully human monoclonal antibody, built on Regeneron's VelocImmune platform, that binds and neutralizes activin A. Activin A is a signaling protein in the TGF-beta superfamily. Regeneron's own scientists discovered why it matters in FOP: the disease is caused by mutations in the ACVR1 gene, which encodes the Activin A receptor type I. Those mutations reprogram the receptor so that activin A - which normally does not trigger bone formation - instead switches on the bone-building cascade. Garetosmab soaks up activin A before it can reach the mutant receptor, shutting off the signal at its source rather than managing flare-ups after they start.
The OPTIMA Phase 3 numbers
OPTIMA was a randomized, double-blind, placebo-controlled Phase 3 trial in 63 adults with active FOP, who received 3 mg/kg garetosmab, 10 mg/kg garetosmab, or placebo intravenously every four weeks for 56 weeks. The results were striking. On the primary endpoint - reduction in the total number of new HO lesions versus placebo (which developed 19 lesions) - the 3 mg/kg group had just 1 new lesion, a 94% reduction (p=0.0274), and the 10 mg/kg group had 2, a 90% reduction (p=0.0260). A post-hoc analysis of lesion volume was even more dramatic: both doses cut the mean total volume of new bone by more than 99% (0.01 and 0.02 cubic centimeters versus 10.45 for placebo). For a disease defined by relentless new bone, near-total suppression is about as close to disease modification as FOP research has come.
Safety - and a hard-earned history
In OPTIMA, serious treatment-emergent adverse events were rare and balanced across arms (1 patient on 3 mg/kg, 2 on 10 mg/kg, 2 on placebo), with no treatment-related deaths reported. The most common side effects, each in at least 30% of patients, were nosebleeds (epistaxis), increased hair growth, abscesses and acne - a signature of activin A and BMP-axis biology. This clean result matters because garetosmab's path was not smooth: the earlier Phase 2 trial, LUMINA-1, saw 5 of 44 patients die during its open-label period, prompting an FDA clinical hold in 2020. Those deaths were judged unlikely to be related to the drug and consistent with the natural history of FOP, and the program was redesigned into OPTIMA. The history is a reminder that long-term safety follow-up remains important even amid strong efficacy.
The regulatory milestone
On February 19, 2026, the FDA accepted garetosmab's Biologics License Application for Priority Review, with a target action date of August 2026. Priority Review is reserved for therapies that could offer significant improvements for serious conditions. Garetosmab already holds FDA Fast Track and Orphan Drug designations and EU Orphan designation, and Regeneron is planning OPTIMA 2, a Phase 3 study in adolescents and children. If approved, it would be the first and only treatment shown to reduce the number and volume of new HO lesions in adults with FOP - a landmark for a community that has had no disease-modifying options.
The second act: saving muscle in obesity
Activin A is not only a bone signal - it is also one of the body's muscle-wasting signals, which is why garetosmab has a surprising second life in obesity research. In Regeneron's Phase 2 COURAGE trial, it is paired with the anti-myostatin antibody trevogrumab on top of semaglutide to counter the muscle loss that comes with GLP-1 weight loss. The semaglutide + trevogrumab + garetosmab triplet produced about 13.4% total weight loss at 26 weeks while keeping more than 80% of lean body mass, and adding garetosmab boosted fat-mass loss by roughly 27.3% over semaglutide alone. Blocking activin A on top of myostatin did double duty - a clean demonstration that both pathways feed the muscle loss seen with incretin therapy. It also places garetosmab in the fast-growing muscle-preservation cluster alongside trevogrumab, apitegromab, bimagrumab and taldefgrobep alfa. For now garetosmab is investigational and not approved for any use, and nothing here is medical advice.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of FOP - Regeneron (February 19, 2026) Source
- [2] Regeneron Announces Positive Phase 3 Trial in Adults with FOP - Regeneron Source
- [3] Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial (LUMINA-1) - Nature Medicine (2023) Source
- [4] Results from Phase 2 COURAGE Trial - Regeneron (September 2025) Source
Related Articles
Apitegromab (SRK-015): The First Muscle-Targeted Myostatin Antibody to Win a Phase 3 - in SMA, and Now Obesity (July 14, 2026)
For two decades, drugging myostatin - the body's brake on muscle growth - was a graveyard of failed trials. Apitegromab changed that. Scholar Rock's antibody binds only the inactive precursor forms of myostatin, and in the Phase 3 SAPPHIRE trial it became the first muscle-targeted therapy to improve motor function in spinal muscular atrophy on top of SMN drugs. Now the same mechanism is showing up in obesity: in Phase 2 EMBRAZE, apitegromab preserved ~55% more lean mass during tirzepatide weight loss. Here is how it works, what the data show, and where its September 30, 2026 FDA decision stands.
Trevogrumab: Regeneron's Myostatin Antibody Aims to Keep the Muscle On During GLP-1 Weight Loss (July 16, 2026)
GLP-1 drugs melt away fat - but about a third of the weight lost is muscle. Regeneron's anti-myostatin antibody trevogrumab (REGN1033) is designed to fix that. In the Phase 2 COURAGE trial, adding it to semaglutide halved lean-mass loss, and a triplet with garetosmab preserved over 80% of muscle while deepening fat loss. Here's where it fits in the muscle-preservation race.